Living Cell Technologies Share Price and Company Fundamentals



Price
$0.013
Change
0.000 (0.000%)
52 week
0.011 - 0.025

Last traded: Today at 12:37 AM

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.

Key Metrics

PE ratio

-

PB ratio

3.25

Dividend yield

Beta

0.67

Market cap

$7.43M

Enterprise value

$5.35M

Company profile

Primary activitiesLiving Cell Technologies - cell therapy for neurodegenerative diseases.
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.lctglobal.com
Mailing address330 Collins Street Level 7 Melbourne VIC 3000 Australia
Phone / Fax61 3 8689 9997 / 61 3 9602 4709
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

Living Cell Technologies does not pay dividends.

Company Executives

As of Aug 2021, following are the company executives and directors listed on Living Cell Technologies.

NameTitleAgeTotal Pay
Dr. Bernard Tuch BSc, FRACP, GAICD, MBBS (Hons), Ph.D.Chairman & Interim CEO6967.08k
Mr. Daya UkaChief Financial Officer144.72k
Dr. Janice LamChief Operating Officer
Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, GAICD, GradDip CSP, FGIACompany Sec.56

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-315.94%

Return on assets

-23.30%

Return on equity

-44.29%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Living Cell Technologies is 7.43M and its enterprise value is 5.35M. The enterprise value to revenue ratio of LCT is 12.34.

The LCT's stocks Beta value is 0.67 making it 33% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Living Cell Technologies (LCT)

Living Cell Technologies (ASX:LCT) Frequently Asked Questions

1. What is Living Cell Technologies's Stock Symbol?

Living Cell Technologies trades on ASX under the ticker symbol "LCT".

2. What is Living Cell Technologies's stock price today?

One share of LCT stock can currently be purchased for approximately $0.013.

3. How can I contact Living Cell Technologies?

Living Cell Technologies's mailing address is 330 Collins Street Level 7 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 8689 9997.

4. What is Living Cell Technologies's official website?

The official website of Living Cell Technologies is http://www.lctglobal.com.

5. Which share registry manages Living Cell Technologies's stock?

Living Cell Technologies's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.